Singapore, Nov. 11 -- 10x Genomics, Inc., the life science technology leader focused on accelerating science and advancing human health, has announced that Fudan University Shanghai Cancer Center (FUSCC) and Shanghai Precision Diagnostics Co. Ltd (SPDx), will deploy its Xenium platform in a 24-month study.

The project seeks to identify biomarkers that may predict how patients with breast cancer respond to neoadjuvant therapy, or treatment administered before surgery to shrink tumors. FUSCC and SPDx intend to use the findings from the study to inform their development of potential future diagnostic approaches.

This study plans to analyse pretreatment tumour biopsy samples from 500 patients receiving neoadjuvant therapy. Researchers will ...